Mature B cells reprogrammed to stem-cell-like state

Fully mature, differentiated B cells can be reprogrammed to an embryonic-stem-cell-like state, without the use of an egg, according to a study published in the April 18 issue of Cell.

In previous research, induced pluripotent stem (IPS) cells typcially have been created from fibroblasts, a specific type of skin cells that may differentiate into other types of skin cells. Because there is no way to tell if the fibroblasts were fully differentiated, the cells used in earlier experiments may have been less differentiated and therefore easier to convert to the embryonic-stem-cell-like state of IPS cells.

B cells are immune cells that can bind to specific antigens, such as proteins from bacteria, viruses or microorganisms. Unlike fibroblasts, mature B cells have a specific part of their DNA cut out as a final maturation step. “Once that piece of DNA is cut out, it can’t come back,” says Jacob Hanna, first author on the paper and a postdoctoral fellow in Whitehead Member Rudolf Jaenisch’s lab. “Checking the genome give us a way to make sure the resulting IPS cells were not from immature cells.”

"In principle, this will allow you to transfer a complex genetic human disease into a Petri dish, and study it," says Whitehead Member Rudolf Jaenisch. "That could be the first step to analyze the disease and to define a therapy.”

Hanna and his colleagues began the experiment by generating IPS cells from immature B cells. Similar to the process used to create IPS cells from fibroblast cells, Hanna successfully reprogrammed the immature B cells into IPS cells by using retroviruses to transfer four genes (Oct4, Sox2, c-Myc and Klf4) into the cells’ DNA.

However, an additional factor, CCAAT/enhancer-binding-protein-á (C/EBPá), was needed to nudge mature B cells to be reprogrammed as IPS cells.

Like IPS cells from earlier fibroblast studies, the IPS cells from both the mature and immature B cells could be used to create mice. The mice grown from the reprogrammed mature B cells were missing the same part of their DNA as the mature B cells, demonstrating that Hanna and his colleagues had successfully reprogrammed fully differentiated cells.

In addition to demonstrating the power of reprogramming, this work offers the promise of powerful new mouse models for autoimmune diseases such as multiple sclerosis and type 1 diabetes, in which the body attacks certain types of its own cells. For example, mature B or T cells specific for nerve cells called glia could be reprogrammed to IPS cells and then used to create mice with an entire immune system that is primed to only attack the glia cells, thereby creating a mouse model for studying multiple sclerosis.

Eventually, researchers will be able to study diseases by following a similar process with human cells, predicts Jaenisch, who is also a professor of biology at Massachusetts Institute of Technology. “In principle, this will allow you to transfer a complex genetic human disease into a Petri dish, and study it,” he says. “That could be the first step to analyze the disease and to define a therapy.”

This research was supported by the National Institutes of Health and the Helen Hay Whitney Foundation.

Written by Nicole Giese.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
AI-powered blood test promises early detection of ovarian cancer